

# Remdesivir - COVID-19 - India

## (Repurposing Scan)

**Report ID:** REP-20251216-633fc9  
**Generated At:** 2025-12-16T11:51:39.871179  
**Format:** pdf

### Executive Summary

- Remdesivir is recognized and utilized in the treatment of COVID-19 with multiple publications from 2019 to 2024 indicating its clinical use, side effects, and treatment outcomes. Authoritative guidelines from WHO and NICE provide general disease management guidance. News sources note remdesivir's emergency approval, use guidelines, export bans, and legal issues in India during the COVID-19 pandemic.

### Clinical Trials

#### Summary

- Active trials: 4
- Completed trials: 1
- Phase distribution: Phase Observational (1) Phase Phase 1 (0) Phase Phase 2 (3) Phase Phase 3 (0) Phase Phase 4 (1)

#### Highlights

- No Phase III trials identified in India

#### Top Trials

Trial ID	Title	Phase	Status	Locations	Start Date
NCT04854837	Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis	Observational	Completed	Hungary	2021-04-12
NCT04386447	Phase II, Multicenter, Open-label, Rct With an Adaptive Design, to Assess Efficacy of	Phase 2	Active	Italy, France	2020-09-01

Trial ID	Title	Phase	Status	Locations	Start Date
	Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19				
NCT04403477	Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT	Phase 2	Active	Bangladesh	2020-05-20
NCT04321993	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients	Phase 2	Active	Canada	2020-04-17
NCT06792214	Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/ Remdesivir Effectiveness For the prEvention of loNg covid (DEFEND) Clinical Trial	Phase 4	Active	Canada	2025-01-03

## Guidelines and Literature

### Guidelines

- **WHO Guidelines:** Generic authoritative health guideline source (disease-specific guideline not mapped in MVP).
- **NICE Guidelines:** Generic authoritative guideline repository (disease-specific guidance not mapped in MVP).

## Publications

- **PMID 39816292 (2024):**
- **PMID 39811032 (2024):**
- **PMID 39739156 (2025):**

## Repurposing Options

---

- **Targeted subgroup usage**

Rationale: Remdesivir is recognized and utilized in the treatment of COVID-19 with multiple publications from 2019 to 2024 indicating its clinical use, side effects, and treatment outcomes. Authoritative guidelines from WHO and NICE provide general disease management guidance. News sources note remdesivir's emergency approval, use guidelines, export bans, and legal issues in India during the COVID-19 pandemic.

Evidence: WHO Guidelines, NICE Guidelines

## Risks and Gaps

---

- Limited late-stage clinical evidence
- Geography-specific data gaps for India

## References

---

- **Guideline:** WHO Guidelines — <https://www.who.int/publications/guidelines>
- **Guideline:** NICE Guidelines — <https://www.nice.org.uk/guidance>
- **Publication:** PMID:39816292 — <https://pubmed.ncbi.nlm.nih.gov/39816292/>
- **Publication:** PMID:39811032 — <https://pubmed.ncbi.nlm.nih.gov/39811032/>
- **Publication:** PMID:39739156 — <https://pubmed.ncbi.nlm.nih.gov/39739156/>
- **Trial:** NCT04854837 — <https://clinicaltrials.gov/study/NCT04854837>
- **Trial:** NCT04386447 — <https://clinicaltrials.gov/study/NCT04386447>
- **Trial:** NCT04403477 — <https://clinicaltrials.gov/study/NCT04403477>
- **Trial:** NCT04321993 — <https://clinicaltrials.gov/study/NCT04321993>
- **Trial:** NCT06792214 — <https://clinicaltrials.gov/study/NCT06792214>

## Warnings

---

- **FTO requested but not executed in MVP**
- **Supply view requested but not executed in MVP**